Mirum Pharmaceuticals Stock Today
| MIRM Stock | USD 46.22 0.43 0.92% |
Performance6 of 100
| Odds Of DistressLess than 20
|
Mirum Pharmaceuticals is selling at 46.22 as of the 1st of December 2024; that is 0.92 percent decrease since the beginning of the trading day. The stock's lowest day price was 46.09. Mirum Pharmaceuticals has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Mirum Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2019 | Category Healthcare | Classification Health Care |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. The company has 48 M outstanding shares of which 6.97 M shares are now shorted by private and institutional investors with about 19.56 trading days to cover. More on Mirum Pharmaceuticals
Moving together with Mirum Stock
Moving against Mirum Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mirum Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Christopher Peetz | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMirum Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mirum Pharmaceuticals' financial leverage. It provides some insight into what part of Mirum Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mirum Pharmaceuticals (MIRM) is traded on NASDAQ Exchange in USA. It is located in 950 Tower Lane, Foster City, CA, United States, 94404 and employs 311 people. Mirum Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.24 B. Mirum Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 48 M outstanding shares of which 6.97 M shares are now shorted by private and institutional investors with about 19.56 trading days to cover.
Mirum Pharmaceuticals currently holds about 124.95 M in cash with (70.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82.
Check Mirum Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Mirum Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mirum Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mirum Pharmaceuticals. Please pay attention to any change in the institutional holdings of Mirum Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Mirum Ownership Details
Mirum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 936.2 K | |
| Clearbridge Advisors, Llc | 2024-09-30 | 889.1 K | |
| Pictet Asset Manangement Sa | 2024-06-30 | 875.1 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 759 K | |
| Lord, Abbett & Co Llc | 2024-09-30 | 741.4 K | |
| Polar Capital Holdings Plc | 2024-06-30 | 741 K | |
| Avidity Partners Management Lp | 2024-09-30 | 731.1 K | |
| First Turn Management Llc | 2024-09-30 | 647.6 K | |
| Hhg Plc | 2024-06-30 | 5 M | |
| Eventide Asset Management, Llc | 2024-09-30 | 3.4 M |
Mirum Pharmaceuticals Historical Income Statement
Mirum Stock Against Markets
Mirum Pharmaceuticals Corporate Management
| Peter MBA | Chief Officer | Profile | |
| Eric MBA | Chief Officer | Profile | |
| Ian Clements | Chief Officer | Profile | |
| Paul Ross | Chief Officer | Profile | |
| Joanne MD | Chief Officer | Profile | |
| MSC MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.